Indonesia authorises Sputnik V: RDIF

The Russian Direct Investment Fund (RDIF) yesterday announced the approval of the Russian Sputnik V COVID-19 vaccine in the Republic of Indonesia.

Indonesia has become the 70th country in the world to register the Russian vaccine. Sputnik V was granted an emergency use authorisation (EUA). The total population of all countries where Sputnik V is approved for use now exceeds four billion people, which is more than half of the global population, RDIF said in a statement.

It also said that the real-world data obtained during vaccination with Sputnik V in a number of countries (Argentina, San Marino, Serbia, Hungary, Bahrain, Mexico, the UAE and others) demonstrate that Sputnik V is one of the safest and most effective vaccines against coronavirus. The Russian vaccine ranks second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators.

Sputnik V has also been approved in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, the UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska (entity of Bosnia and Herzegovina), Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon, San-Marino, Ghana, Syria, Kyrgyzstan, Guyana, Egypt, Honduras, Guatemala, Moldova, Slovakia, Angola, Republic of the Congo, Djibouti, Sri Lanka, Laos, Iraq, North Macedonia, Kenya, Morocco, Jordan, Namibia, Azerbaijan, Philippines, Cameroon, Seychelles, Mauritius, Vietnam, Antigua and Barbuda, Mali, Panama, India, Nepal, Bangladesh, Turkey, Albania, Maldives, Ecuador, Brazil, Nigeria and Chile, notified the statement.

Speaking on this, Kirill Dmitriev, CEO, RDIF, said, “Indonesia is one of the most populated nations in Asia and inclusion of Sputnik V in the national vaccine portfolio will provide for using one of the safest and most effective vaccines in the world. Sputnik V is based on a proven human adenoviral vectors platform and is successfully used in over 50 countries. Approval in Indonesia is based on the results of a comprehensive assessment of the vaccine and will make an important contribution in the country’s fight against the pandemic.”